Document Detail


Early statin therapy in acute coronary syndromes.
MedLine Citation:
PMID:  14551525     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Patients who survive an acute coronary syndrome are at much higher risk of a recurrent event within the following year than patients with stable coronary syndromes. Risk factor modification, including statin therapy, lowers the risk of recurrent events over many years, but also to reduces the high risk of an another event within the weeks to months following the initial acute coronary syndrome. The mechanisms that contribute to this benefit are likely related to improvements in endothelial function, a decrease in vascular inflammation, and reduced prothrombotic factors. The effects of statins may be mediated by cholesterol reduction, cholesterol-independent effects (particularly by decreasing isoprenoids), and mechanisms that are independent of inhibiting HMG CoA reductase. Observational studies show an early reduction in mortality with statin therapy started before discharge from hospital after an acute coronary syndrome. Several randomized controlled trials also support a rapid reduction in the risk of recurrent events after starting statins during the hospital admission for an acute coronary syndrome. Early statin therapy is also related to improved compliance and use of statins several years after a coronary event. Thus early statin therapy may improve both early and long-term secondary prevention efforts.
Authors:
S Kinlay
Related Documents :
19389675 - The watanabe heritable hyperlipidemic (whhl) rabbit, its characteristics and history of...
12137255 - Apolipoprotein(a) phenotypes predict the severity of coronary artery stenosis.
20684825 - Correlation between circulating adiponectin levels and coronary plaque regression durin...
3986055 - Family history of myocardial infarction as an independent risk factor for coronary hear...
19942415 - The role of lymphatic vessels in the heart.
20856175 - Low hemoglobin levels during normovolemia are associated with electrocardiographic chan...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Minerva cardioangiologica     Volume:  51     ISSN:  0026-4725     ISO Abbreviation:  Minerva Cardioangiol     Publication Date:  2003 Oct 
Date Detail:
Created Date:  2003-10-10     Completed Date:  2004-06-21     Revised Date:  2005-11-16    
Medline Journal Info:
Nlm Unique ID:  0400725     Medline TA:  Minerva Cardioangiol     Country:  Italy    
Other Details:
Languages:  eng     Pagination:  577-84     Citation Subset:  IM    
Affiliation:
Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA. skinlay@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Angina, Unstable / drug therapy*
Arteriosclerosis / prevention & control
Coronary Disease / drug therapy*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Myocardial Infarction / drug therapy*
Syndrome
Time Factors
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Omega-3 polyunsaturated fatty acids and cardiovascular diseases
Next Document:  Balancing benefit against risk in the choice of therapy for coronary artery disease. Lesson from pro...